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Circadian rhythm of exhaled biomarkers
in health and asthma
To the Editor:
Circadian rhythms regulate and reflect many biological processes. Investigating circadian variability in
biomarkers is important since the diurnal variability of any potential biomarker must be quantified and
controlled in research and clinical practice. Time of day is particularly important in inflammatory diseases
such as asthma, which are linked to exaggerated circadian rhythms. Airway narrowing in asthma is
greatest at around 04:00 h and coincides with an increase in symptoms; asthma deaths are also more likely
to occur at this time [1, 2]. Likewise eosinophilic airway inflammation peaks in the morning, with clinical
implications for biomarker-guided steroid therapy [3].
As asthma is a circadian disease, we expected to observe newly rhythmic volatile organic compounds
(VOCs) in breath when compared to a healthy population. Therefore, we investigated how exhaled VOCs
and exhaled nitric oxide fraction (FeNO) vary over the 24-h cycle in healthy individuals and in those with
asthma.
During an overnight visit to the research unit, exhaled breath was collected and FeNO was measured at
16:00 h, 22:00 h, 04:00 h and 10:00 h. Participants took standardised meals at regular intervals and kept
their usual bedtime. Inhaled corticosteroids (ICS) were omitted 12 h prior to measurements. The study
protocol received ethical approval (ref: 14/NW/1352) and participants provided written informed consent.
FeNO measurements were performed (NIOX Vero; Aerocrine, Solna, Sweden) prior to VOC collection and
spirometry as per manufacturer’s recommendations. For VOC analyses 1-L of breath was collected across
sorbent tubes packed with Carbograph 1TD/Carbograph 5TD (Markes International, Llantrisant, UK), at a
flow rate of 500 mL·min−1 using an in-house sampler described elsewhere [4]. A background air sample
was taken at every time-point by strapping the mask to a glass head and sampling 1 L of filtered air.
Sorbent tubes were sealed and refrigerated immediately after sampling and analysed within 1 month. The
thermal desorption-gas chromatography-mass spectrometry protocol has been published previously [5].
All VOC data files were converted to the open mzXML format prior to pre-processing. Chromatograms
were screened for inclusion in the final dataset by manual appraisal and all samples were deconvolved and
aligned using eRah. A hierarchical Gaussian process model was used to detect oscillating VOCs. Data were
z-normalised on individual patients and compounds, and modelled as Gaussian processes with
exponential covariance functions. The mean function of these Gaussian processes was then modelled using
another Gaussian process, shared across patients, with zero mean and a periodic covariance (24 h period).
This enables the model to account for inter-compound and inter-patient variation separately. The model
was fitted using Hamiltonian Monte Carlo. Empirical p-values were obtained using Monte Carlo
simulation from a null distribution of simulated non-rhythmic data and false discovery rates calculated.
Analyses were implemented in R and Stan.
Compounds of interest were putatively identified using the National Institute of Standards and Technology
library following the metabolomics standards initiative. VOCs were screened to remove common
contaminants arising from the sampling equipment and any VOCs found to be rhythmic in the
background samples.
Data from one patient with asthma were excluded due to technical faults with the GC-MS, leaving
complete datasets for 10 healthy individuals and nine with asthma. The groups were matched for median
(IQR) age (45.5 (27.5–49.3) versus 47.0 (26.0–49.5) years, p=0.92), body mass index (27.1 (23.4–30.5)
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versus 26.9 (22.3–27.2) kg·m−2, p=0.5) and male:female sex ratio (7:3 versus 7:2, p=1). All individuals with
asthma were atopic with significantly lower median (IQR) forced expiratory volume in 1 s compared to
healthy subjects (82.3 (73.0–89.0) versus 97.7 (91.7–105.3) % predicted, p=0.02) and median (IQR)
prescribed daily ICS (equivalent to beclomethasone dipropionate) 400 (400–500) µg.
Of 76 breath samples collected (four time-points per participant), six were removed from the analysis due
to errors in sampling or analytical processing. Background samples were collected at 59 time-points
immediately prior to breath sampling (15 background samples were excluded due to errors in sampling or
analytical processing). A mean±standard deviation of 312±45 compounds were detected in the breath
samples. Once aligned and quality checked to remove contaminant compounds and deconvolution
artefacts 102 VOCs were included in the Gaussian process analysis.
In the combined dataset, five VOCs were shown to be rhythmic (false discovery rate p<0.01).
Dimethoxymethane, chlorobenzene and an unidentified VOC (m/z 56) showed a nadir in the morning,
whereas the opposite diurnal pattern was seen for isoprene and 1-butoxy, 2-propanol (figure 1).
Four VOCs were rhythmic with p<0.05 but not significant after false discovery rate correction; acetone and
1-butanol were highest at 10:00 h and lowest at 16:00 h while xylene and phenol showed the reverse pattern.
A secondary analysis of the data was performed to investigate the rhythmic nature of VOCs associated
with asthma. Camphene was annotated as being rhythmic only in asthma (p<0.05), with a peak at 10:00 h
and a nadir at 16:00 h. Acetone and isoprene (both rhythmic in the combined analysis) were also found to
be rhythmic in the asthma group alone. Two compounds were shown to be rhythmic in the healthy group
but not the asthmatic group (xylene and isobutylacetate). Both demonstrated rhythms in anti-phase with
VOCs found to be rhythmic in asthma only, namely a peak at 16:00 h and a trough at 10:00 h.
A rhythmic cycle for FeNO (p<0.05) was detected only in the asthmatic group, with a peak at 10:00 h and
nadir overnight. The median (IQR) FeNO was 37.5 (18.3–78.0) ppb at 10:00 h and 25.5 (14.7–56.6) ppb at
04:00 h (figure 1).
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FIGURE 1 Circadian analysis of a) the pooled dataset of 19 participants for the compounds that had a false discovery rate q<0.05 after the
Gaussian process analysis was applied and b) compounds found to be rhythmic in either the asthmatic or healthy cohort in a sub group analysis.
Z-score values are shown in light grey with the fitted rhythm overlaid. All compounds were identified as rhythmic with a p-value <0.05 using the
Gaussian process analysis. #: compounds were identified to metabolomics standards initiative level 1, otherwise compounds were identified to
level 2. FeNO: exhaled nitric oxide fraction.
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We have demonstrated that there is rhythmic variability in a proportion of exhaled VOCs over 24 h.
Furthermore, when comparing asthmatic to healthy breath differential patterns of VOC release were
observed. Acetone is the most abundant VOC in breath and has been previously linked to asthma [6, 7].
Changes in the level of acetone overnight in this study replicate findings by KING et al. [8]. Isoprene, the
next most abundant VOC in breath, has also been linked to asthma [6, 9, 10]. Similar to acetone the
changes observed in the levels of isoprene agree with previous work [8, 11]. For both VOCs, this study
provides insight into the diurnal pattern of expression, adding to the nocturnal profiling detailed in the
literature.
Camphene and xylene have been included in models to distinguish asthma from healthy controls [4, 12]
where they were shown to be reduced in the asthmatic cohort. Camphene has also been shown to inhibit
the release of nitric oxide in stressed rat macrophages [13]. All other VOCs shown to be rhythmic in this
work have previously been found in breath and have been linked to a variety of diseases.
We have also shown that FeNO demonstrates a strong circadian rhythm in asthma with lower levels
detected during the night than during the day. FeNO is used in diagnostic asthma algorithms with cut-offs
varying between 25 ppb [14] and 35–40 ppb [15]. We found the diurnal FeNO variability straddled these
cut-offs and it is crucial that larger studies validate our findings, which may impact on diagnostic
recommendations.
In addition to the clinical implications, this work demonstrates that time of day is an important parameter
to consider when undertaking VOC sampling, especially in untargeted hypothesis-generating studies.
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